Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of PRM-151 in healthy volunteers and patients with idiopathic pulmonary fibrosis
NL-OMON33156Phase 1Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in idiopathic pulmonary fibrosis (IPF) and fibrosis comparing PRM-151 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2009; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)fibrosis
Beyond the preview
Go deeper on NL-OMON33156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33156.